Horizon Pharma, Inc. has entered into an agreement with AstraZeneca to acquire the U.S. rights to Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets, indicated to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of stomach ulcers. AstraZeneca will retain rights outside the U.S.
 
“The acquisition of Vimovo is a major step forward in our strategy to leverage our business model and maximize our commercial infrastructure and we expect it to create significant value for our shareholders,” said Timothy P. Walbert, chairman, president and chief executive officer of Horizon. “We anticipate that this transaction will significantly increase our revenues and accelerate the Company to profitable operations.”